Fas receptor: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
| update_citations = yes | | update_citations = yes | ||
}} | }} | ||
<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot. See Template:PBB_Controls to Stop updates. --> | <!-- The GNF_Protein_box is automatically maintained by Protein Box Bot. See Template:PBB_Controls to Stop updates. --> | ||
{{GNF_Protein_box | {{GNF_Protein_box | ||
Line 50: | Line 49: | ||
}} | }} | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 11:35, 5 September 2011
Fas death domain (TNF receptor superfamily, member 6) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PDB rendering based on 1ddf. | |||||||||||||
| |||||||||||||
Identifiers | |||||||||||||
Symbols | FAS ; ALPS1A; APO-1; APT1; CD95; FAS1; FASTM; TNFRSF6 | ||||||||||||
External IDs | Template:OMIM5 Template:MGI HomoloGene: 27 | ||||||||||||
| |||||||||||||
RNA expression pattern | |||||||||||||
More reference expression data | |||||||||||||
Orthologs | |||||||||||||
Template:GNF Ortholog box | |||||||||||||
Species | Human | Mouse | |||||||||||
Entrez | n/a | n/a | |||||||||||
Ensembl | n/a | n/a | |||||||||||
UniProt | n/a | n/a | |||||||||||
RefSeq (mRNA) | n/a | n/a | |||||||||||
RefSeq (protein) | n/a | n/a | |||||||||||
Location (UCSC) | n/a | n/a | |||||||||||
PubMed search | n/a | n/a |
WikiDoc Resources for Fas receptor |
Articles |
---|
Most recent articles on Fas receptor Most cited articles on Fas receptor |
Media |
Powerpoint slides on Fas receptor |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Fas receptor at Clinical Trials.gov Clinical Trials on Fas receptor at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Fas receptor
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Fas receptor Discussion groups on Fas receptor Patient Handouts on Fas receptor Directions to Hospitals Treating Fas receptor Risk calculators and risk factors for Fas receptor
|
Healthcare Provider Resources |
Causes & Risk Factors for Fas receptor |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The Fas receptor (FasR) is the most intensely studied death receptor. Its aliases include CD95, Apo-1, and tumor necrosis factor receptor superfamily, member 6 (TNFRSf6). The gene is situated on chromosome 10 in humans and 19 in mice.
Isoforms
Previous reports have identified as many as eight splice variants, which are translated into seven isoforms of the protein.
Many of these isoforms are rare haplotypes that are usually associated with a state of disease.
Apoptosis-inducing Fas receptor is dubbed isoform 1 and is a type 1 transmembrane protein.
Function
Fas forms the death inducing signalling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of Fas receptor. This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal induced by the antibody is unreliable in the study of Fas signaling. To this end, several clever ways of trimerizing the antibody for in vitro research have been employed.
Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain.[1]
FADD also contains a death effector domain (DED) near its amino terminus,[2]which facilitates binding to the DED of FADD-like ICE (FLICE), more commonly referred to as caspase-8. FLICE can then self-activate through proteolytic cleavage into p10 and p18 subunits, two each of which form the active heterotetramer enzyme. Active caspase-8 is then released from the DISC into the cytosol, where it cleaves other effector caspases, eventually leading to DNA degradation, membrane blebbing, and other hallmarks of apoptosis.
Role in apoptosis
Some reports have suggested that the extrinsic Fas pathway is sufficient to induce complete apoptosis in certain cell types through DISC assembly and subsequent caspase-8 activation.
These cells are dubbed Type 1 cells and are characterized by the inability of anti-apoptotic members of the Bcl-2 family (namely Bcl-2 and Bcl-xL) to protect from Fas-mediated apoptosis.
Characterized Type 1 cells include H9, CH1, SKW6.4 and SW480, all of which are lymphocyte lineages except the latter, which is a colon adenocarcinoma lineage.
However, evidence for crosstalk between the extrinsic and intrinsic pathways exists in the Fas signal cascade.
In most cell types, caspase-8 catalyzes the cleavage of the pro-apoptotic BH3-only protein Bid into its truncated form, tBid. BH-3 only members of the Bcl-2 family exclusively engage anti-apoptotic members of the family (Bcl-2, Bcl-xL), allowing Bak and Bax to translocate to the outer mitochondrial membrane, thus permeabilizing it and facilitating release of pro-apoptotic proteins such as cytochrome c and Smac/DIABLO, an antagonist of inhibitors of apoptosis proteins (IAPs).
References
- ↑ Huang B; et al. (1996). "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain". Nature. 384: 638–41.
- ↑ Eberstadt M; et al. (1998). "NMR structure and mutagenesis of the FADD (Mort1) death-effector domain". Nature. 391: 941–5.
Further reading
- Nagata S (1997). "Apoptosis by death factor". Cell. 88 (3): 355–65. PMID 9039262.
- Cascino I, Papoff G, Eramo A, Ruberti G (2004). "Soluble Fas/Apo-1 splicing variants and apoptosis". Front. Biosci. 1: d12–8. PMID 9159204.
- Uckun FM (1998). "Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis". Biochem. Pharmacol. 56 (6): 683–91. PMID 9751072.
- Krammer PH (2000). "CD95's deadly mission in the immune system". Nature. 407 (6805): 789–95. doi:10.1038/35037728. PMID 11048730.
- Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2001). "The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity". Nat. Immunol. 1 (6): 469–74. doi:10.1038/82712. PMID 11101867.
- Wajant H (2002). "The Fas signaling pathway: more than a paradigm". Science. 296 (5573): 1635–6. doi:10.1126/science.1071553. PMID 12040174.
- Yonehara S (2003). "Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody". Cytokine Growth Factor Rev. 13 (4–5): 393–402. PMID 12220552.
- Choi C, Benveniste EN (2004). "Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses". Brain Res. Brain Res. Rev. 44 (1): 65–81. PMID 14739003.
- Poppema S, Maggio E, van den Berg A (2004). "Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations". Leuk. Lymphoma. 45 (3): 423–31. PMID 15160902.
External links
- fas+Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)